Stock Market & Financial Investment News

News Breaks January 29, 2013 07:36 EDT KERX Keryx Biopharmaceuticals price target raised to $11 from $3 at Oppenheimer Oppenheimer increased its target on Keryx after the company reported stronger than expected data for its Phase III trial evaluating Zerenex for the treatment of hyperphosphatemia in dialysis patients. The firm believes that Zerenex is very attractive from a commercial perspective, and it reiterates an Outperform rating on the stock. News For KERX From The Last 14 Days Check below for free stories on KERX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 10, 2013 11:08 EDT KERX Keryx management to meet with Oppenheimer Subscribe for More Information May 7, 2013 16:47 EDT KERX Keryx reports Q1 EPS with items (3c), consensus (1c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.